CancerNetwork®’s Week in Review: June 1, 2021
Look back at some of the important news and notes from last week you might have missed in the world of oncology from the FDA and the journal ONCOLOGY®.
Each Monday, CancerNetwork® highlights the most important content from the previous week in oncology news.
Last week featured an interview with a key opinion leader from the American Association for Cancer Research Annual Meeting 2021 and a pair of FDA approvals for 18F-DCFPyL and Camcevi for the treatment of prostate cancer.
CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 about data supporting the potential use of the combination exemestane (Aromasin)/leuprolide acetate (Lupron Depot) plus pembrolizumab (Keytruda).
She detailed findings from a phase 1b/2 study in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
FDA Approves 18F-DCFPyL as First PSMA PET Imaging Agent Available for Prostate Cancer
The approval of 18F-DCFPyL comes on the heels of positive results from the company-sponsored research in the CONDOR and OSPREY trials investigating the imaging agent for prostate cancer.
18F-DCFPyL is now the first commercially available PSMA PET imaging agent for prostate cancer, working to identify suspected metastasis or recurrence in patients with prostate cancer.
Real-World Data Support the Use of Later-Line Eribulin in Metastatic Breast Cancer
Investigators aimed to determine if oncologic outcomes of patients in the real-world setting matched those of a pivotal clinical trial that led to the approval of eribulin mesylate in patients with metastatic breast cancer.
The agent, which was approved in 2010, treats patients who have received at least 2 prior lines of chemotherapy in the adjuvant or metastatic setting, including an anthracycline and taxane.
FDA Approves Subcutaneous Depot Formulation of Leuprolide Mesylate for Prostate Cancer
The ready-to-use subcutaneous formulation of leuprolide mesylate, Camcevi, was approved for use in patients with prostate cancer by the FDA.
Data supporting the approval are from a phase 3 trial of 137 patients who were treated with the 42-mg formulation every 6 months. The results indicated the efficacy and safety of the agent, meeting the primary end point of the proportion of patients with serum testosterone suppression by day 28 and from day 28 through 336 in the intention-to-treat population.
This review article published in the journal ONCOLOGY® looks at the successful clinical development of immunotherapies, PARP inhibitors, and antibody-drug conjugates for the management of metastatic triple-negative breast cancer and how these have improved the survival outcome of patients.
Over the coming years, therapeutic developments in precision medicine will likely change the treatment landscape and might make the current definition of triple-negative breast cancer as a disease that is estrogen receptor, progesterone receptor, and HER2 negative obsolete.
For more updates from CancerNetwork®, make sure to follow us on Facebook, Twitter, and LinkedIn to stay up to date on the latest in oncology.
